The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease

Sofie M Adriaanse; Koene R A van Dijk; Rik Ossenkoppele; Martin Reuter; Nelleke Tolboom; Marissa D Zwan; Maqsood Yaqub; Ronald Boellaard; Albert D Windhorst; Wiesje M van der Flier; Philip Scheltens; Adriaan A Lammertsma; Frederik Barkhof; Bart N M van Berckel

doi:10.1007/s00259-014-2704-z

The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease

Sofie M Adriaanse^*, Koene R A van Dijk, Rik Ossenkoppele, Martin Reuter, Nelleke Tolboom, Marissa D Zwan, Maqsood Yaqub, Ronald Boellaard, Albert D Windhorst, Wiesje M van der Flier, Philip Scheltens, Adriaan A Lammertsma, Frederik Barkhof, Bart N M van Berckel

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

PURPOSE: The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer's disease (AD) patients and healthy elderly controls.

METHODS: Structural MRI scans of eleven AD patients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [(11)C]PIB to assess amyloid-β plaque load and [(18)F]FDG to assess glucose metabolism. [(11)C]PIB binding and [(18)F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD.

RESULTS: While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of AD patients was significantly related to volume loss over time (rho = 0.56, p < 0.05).

CONCLUSION: The present study shows that in a group of AD patients amyloid-β plaque load as measured by [(11)C]PIB behaves as a trait marker (i.e., all AD patients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [(18)F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.

Original language	English
Pages (from-to)	1190-1198
Number of pages	9
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	41
Issue number	6
DOIs	https://doi.org/10.1007/s00259-014-2704-z
Publication status	Published - Jun 2014
Externally published	Yes

Keywords

Aged
Alzheimer Disease/diagnostic imaging
Aniline Compounds
Benzothiazoles/pharmacokinetics
Cerebral Cortex/diagnostic imaging
Female
Fluorodeoxyglucose F18/pharmacokinetics
Glucose/metabolism
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Plaque, Amyloid/diagnostic imaging
Positron-Emission Tomography
Radiopharmaceuticals/pharmacokinetics
Thiazoles

Access to Document

10.1007/s00259-014-2704-z

Cite this

Adriaanse, S. M., van Dijk, K. R. A., Ossenkoppele, R., Reuter, M., Tolboom, N., Zwan, M. D., Yaqub, M., Boellaard, R., Windhorst, A. D., van der Flier, W. M., Scheltens, P., Lammertsma, A. A., Barkhof, F., & van Berckel, B. N. M. (2014). The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 41(6), 1190-1198. https://doi.org/10.1007/s00259-014-2704-z

@article{656fdfb4f7d94297993131c213a5fd10,

title = "The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease",

abstract = "PURPOSE: The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer's disease (AD) patients and healthy elderly controls.METHODS: Structural MRI scans of eleven AD patients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [(11)C]PIB to assess amyloid-β plaque load and [(18)F]FDG to assess glucose metabolism. [(11)C]PIB binding and [(18)F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD.RESULTS: While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of AD patients was significantly related to volume loss over time (rho = 0.56, p < 0.05).CONCLUSION: The present study shows that in a group of AD patients amyloid-β plaque load as measured by [(11)C]PIB behaves as a trait marker (i.e., all AD patients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [(18)F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.",

keywords = "Aged, Alzheimer Disease/diagnostic imaging, Aniline Compounds, Benzothiazoles/pharmacokinetics, Cerebral Cortex/diagnostic imaging, Female, Fluorodeoxyglucose F18/pharmacokinetics, Glucose/metabolism, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Plaque, Amyloid/diagnostic imaging, Positron-Emission Tomography, Radiopharmaceuticals/pharmacokinetics, Thiazoles",

author = "Adriaanse, {Sofie M} and {van Dijk}, {Koene R A} and Rik Ossenkoppele and Martin Reuter and Nelleke Tolboom and Zwan, {Marissa D} and Maqsood Yaqub and Ronald Boellaard and Windhorst, {Albert D} and {van der Flier}, {Wiesje M} and Philip Scheltens and Lammertsma, {Adriaan A} and Frederik Barkhof and {van Berckel}, {Bart N M}",

year = "2014",

month = jun,

doi = "10.1007/s00259-014-2704-z",

language = "English",

volume = "41",

pages = "1190--1198",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer-Verlag",

number = "6",

}

Adriaanse, SM, van Dijk, KRA, Ossenkoppele, R, Reuter, M, Tolboom, N, Zwan, MD, Yaqub, M, Boellaard, R, Windhorst, AD, van der Flier, WM, Scheltens, P, Lammertsma, AA, Barkhof, F & van Berckel, BNM 2014, 'The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease', European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 6, pp. 1190-1198. https://doi.org/10.1007/s00259-014-2704-z

TY - JOUR

T1 - The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease

AU - Adriaanse, Sofie M

AU - van Dijk, Koene R A

AU - Ossenkoppele, Rik

AU - Reuter, Martin

AU - Tolboom, Nelleke

AU - Zwan, Marissa D

AU - Yaqub, Maqsood

AU - Boellaard, Ronald

AU - Windhorst, Albert D

AU - van der Flier, Wiesje M

AU - Scheltens, Philip

AU - Lammertsma, Adriaan A

AU - Barkhof, Frederik

AU - van Berckel, Bart N M

PY - 2014/6

Y1 - 2014/6

N2 - PURPOSE: The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer's disease (AD) patients and healthy elderly controls.METHODS: Structural MRI scans of eleven AD patients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [(11)C]PIB to assess amyloid-β plaque load and [(18)F]FDG to assess glucose metabolism. [(11)C]PIB binding and [(18)F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD.RESULTS: While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of AD patients was significantly related to volume loss over time (rho = 0.56, p < 0.05).CONCLUSION: The present study shows that in a group of AD patients amyloid-β plaque load as measured by [(11)C]PIB behaves as a trait marker (i.e., all AD patients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [(18)F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.

AB - PURPOSE: The present multimodal neuroimaging study examined whether amyloid pathology and glucose metabolism are related to cortical volume loss over time in Alzheimer's disease (AD) patients and healthy elderly controls.METHODS: Structural MRI scans of eleven AD patients and ten controls were available at baseline and follow-up (mean interval 2.5 years). Change in brain structure over time was defined as percent change of cortical volume within seven a-priori defined regions that typically show the strongest structural loss in AD. In addition, two PET scans were performed at baseline: [(11)C]PIB to assess amyloid-β plaque load and [(18)F]FDG to assess glucose metabolism. [(11)C]PIB binding and [(18)F]FDG uptake were measured in the precuneus, a region in which both amyloid deposition and glucose hypometabolism occur early in the course of AD.RESULTS: While amyloid-β plaque load at baseline was not related to cortical volume loss over time in either group, glucose metabolism within the group of AD patients was significantly related to volume loss over time (rho = 0.56, p < 0.05).CONCLUSION: The present study shows that in a group of AD patients amyloid-β plaque load as measured by [(11)C]PIB behaves as a trait marker (i.e., all AD patients showed elevated levels of amyloid, not related to subsequent disease course), whilst hypometabolism as measured by [(18)F]FDG changed over time indicating that it could serve as a state marker that is predictive of neurodegeneration.

KW - Aged

KW - Alzheimer Disease/diagnostic imaging

KW - Aniline Compounds

KW - Benzothiazoles/pharmacokinetics

KW - Cerebral Cortex/diagnostic imaging

KW - Female

KW - Fluorodeoxyglucose F18/pharmacokinetics

KW - Glucose/metabolism

KW - Humans

KW - Longitudinal Studies

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Plaque, Amyloid/diagnostic imaging

KW - Positron-Emission Tomography

KW - Radiopharmaceuticals/pharmacokinetics

KW - Thiazoles

U2 - 10.1007/s00259-014-2704-z

DO - 10.1007/s00259-014-2704-z

M3 - Article

C2 - 24615466

SN - 1619-7070

VL - 41

SP - 1190

EP - 1198

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 6

ER -

The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this